Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece

  • Ioannis Katsarolis1Email author,
  • Garyphallia Poulakou1,
  • Antonios Analitis2,
  • Irini Matthaiopoulou1,
  • Emmanuel Roilides3,
  • Charalampos Antachopoulos3,
  • Dimitrios A Kafetzis4,
  • Georgios L Daikos5,
  • Regina Vorou1,
  • Christina Koubaniou6,
  • Ioannis Pneumatikos7,
  • Georgios Samonis8,
  • Vasiliki Syriopoulou9,
  • Helen Giamarellou1 and
  • Kyriaki Kanellakopoulou1
BMC Infectious Diseases20099:120

DOI: 10.1186/1471-2334-9-120

Received: 20 July 2008

Accepted: 29 July 2009

Published: 29 July 2009

Abstract

Background

A nation-wide surveillance study was conducted in Greece in order to provide a representative depiction of pneumococcal carriage in the pre-vaccination era and to evaluate potential risk factors for carriage of resistant strains in healthy preschool children attending daycare centers.

Methods

A study group was organized with the responsibility to collect nasopharyngeal samples from children. Questionnaires provided demographic data, data on antibiotic consumption, family and household data, and medical history data. Pneumococcal isolates were tested for their susceptibility to various antimicrobial agents and resistant strains were serotyped.

Results

Between February and May 2004, from a total population of 2536 healthy children, a yield of 746 pneumococci was isolated (carriage rate 29.41%). Resistance rates differed among geographic regions. Recent antibiotic use in the last month was strongly associated with the isolation of resistant pneumococci to a single or multiple antibiotics. Serotypes 19F, 14, 9V, 23F and 6B formed 70.6% of the total number of resistant strains serotyped.

Conclusion

Recent antibiotic use is a significant risk factor for the colonization of otherwise healthy children's nasopharynx by resistant strains of S pneumoniae. The heptavalent pneumococcal conjugate vaccine could provide coverage for a significant proportion of resistant strains in the Greek community. A combined strategy of vaccination and prudent antibiotic use could provide a means for combating pneumococcal resistance.

Background

Streptococcus pneumoniae is the most commonly isolated pathogen in community-acquired respiratory tract infections, being the causative agent of a variety of infections, such as acute otitis media, sinusitis and pneumonia [1]. The development of antibiotic resistance in S pneumoniae over the last two decades has raised a global concern [2], an evolution generally attributed to an extensive consumption of antibiotics [3].

The nasopharynx of preschool children is the ecological niche of S pneumoniae [4]. Nasopharyngeal colonization is a prerequisite for progression to pneumococcal disease and an important source of horizontal spread in the community, especially in settings with high crowding index [1]. Antibiotic-resistant pneumococci involve mostly only a few serogroups in the majority of developed countries (6, 9, 14, 19 and 23). The routine immunization with the heptavalent pneumococcal conjugate vaccine has been shown to decrease the incidence of vaccine-type antibiotic-resistant pneumococci both in invasive diseases; nasopharyngeal colonization was also dramatically decreased in vaccinated individuals and their contacts [5].

In Greece, surveillance studies addressing the issue of resistance and serotype distribution in nasopharyngeal isolates of Streptococcus pneumoniae have been conducted in recent years [6, 7]. Although these studies covered specific regions of the Greek territory, a rise in the frequency of antibiotic-resistant pneumococci has been documented. Recently, another study [8] assessed at regional level the impact of the heptavalent pneumococcal vaccination on the nasopharyngeal carriage of penicillin-resistant pneumococci among day-care attendees.

The heptavalent pneumococcal conjugate vaccine became available in October 2004 and formed part of the national immunization schedule in January 2006. Between February and May 2004 (pre-vaccination era), the present large-scale study was conducted in Greece, through a multi-center initiative task force, in order to provide for the first time a nation-wide representative depiction of carriage of pneumococcal strains isolated from the nasopharynx of healthy preschool children, attending daycare centers and kindergartens. Data on resistance rates and serotype distribution at nation-wide level from this study were published in correlation with data for clinical strains from children and adults for the same period of time [9]. The purpose of the present article is to identify and evaluate risk factors for carriage of resistant pneumococcal strains in this specific population in the pre-vaccination era.

Methods

Study group and study population

A study group of 12 hospitals was organized under the coordination of the 4th Department of Internal Medicine and the Infectious Diseases Laboratory of Athens University Medical School (see Acknowledgements section). The research protocol was approved by the Ministries of Health and Education and the Ethics Committees of all cooperating hospitals. A network was formed consisting of local teams with the responsibility to inform parents and collect appropriately filled questionnaires, collect and culture nasopharyngeal samples from the children, isolate presumed pneumococcal strains, store and ship isolated strains to the central laboratory (Laboratory for Infectious Diseases and Antimicrobial Chemotherapy, 4th Dept of Internal Medicine, Athens University School of Medicine, University General Hospital ATTIKON). The single central laboratory undertook the microbiological procedures and the input of data from the questionnaires in a purpose-structured database.

Questionnaires were distributed to the parents by the local teams of doctors visiting the day-care centres 1–2 days before the sampling visit. On the sampling day, questionnaires were reviewed by the doctors' team. In the section of recent antibiotic use, parents were asked to provide generic or commercial names of all medications received in the last month or trimester and the appropriate classification was performed by the responsible doctors in the sampling site. Questionnaires were signed by the parents, were anonymous but labeled to match the respective sample per child, and consisted of three parts: a) demographic data, i.e. age, gender, name of daycare center, area and prefecture; b) data on antibiotic consumption in the last month and in the last trimester preceding the sampling, including: number of antibiotic courses, name of antimicrobial and reason for its prescription, mode of supply (over-the-counter or by prescription), c) family and household data, i.e. parents working in health care, number of siblings <8 years of age, and d) co morbidities and past medical history data: admission to hospital in the last year, history of « respiratory tract infections », otitis media history in the previous year and steroid use. Children without signed questionnaires by the parents were excluded from sampling, as well as those receiving antibiotics for active infection. Samples without appropriately filled questionnaires were microbiologically processed but were excluded from risk factor analysis.

Sampling procedure and microbiological process of pneumococcal strains

The period of sampling started February 2004 and lasted until the end of May 2004. Carriage samples were collected per nasally with sterile swabs on flexible aluminium wire (Medical Wire & Equipment, Corsham, UK). Swabs were immediately plated on Columbia agar plates (Becton Dickinson, Sparks, MD) supplemented with 5% defibrinated horse blood and packed in 5% CO2 Gas Pak Pouches (Becton Dickinson).

Streptococcus pneumoniae isolates were identified by standard microbiological procedures. Susceptibility testing was performed with the E-test methodology (AB Biodisk, Solna, Sweden) for penicillin(PG), cefuroxime (CXM), ceftriaxone(CTX), erythromycin(ERY), trimethoprim/sulfamethoxazole (COT), tetracycline (TET), moxifloxacin, levofloxacin and ciprofloxacin (CIP). Strains displaying resistance were serotyped by the Quellung reaction using the 12 pooled antisera Pneumotest panel and selected factor sera (Statens Serum Institut, Copenhagen, Denmark). Methodology of sampling, isolation, identification and serotyping of pneumococcal strains, as well as susceptibility testing is mentioned elsewhere in detail [9].

Definitions of terms

Clinical and Laboratory Standards Institute methodology and breakpoints for non-susceptibility and resistance were used for all antibiotics [10], except for ciprofloxacin. For ciprofloxacin, the epidemiological cut-off of 2 mg/L was used as an indicator of resistance, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2006 recommendations [11]. Strains with an MIC value higher than the susceptibility breakpoint were characterized as "non-susceptible", i.e. intermediate and fully resistant strains. Combined resistance was defined as resistance to two different classes of antibiotics (e.g. penicillin and erythromycin) irrespective of other classes. Multiple resistance (or multi-resistance) was defined as resistance to 3 or more antibiotics of different classes [2].

Statistical analysis

Potential risk factors for carriage of pneumococci and in particular of resistant pneumococcal strains were identified by univariate analysis. Antibiotic use was further analyzed using multivariate logistic regression analysis, controlling for variables that were significant in the univariate analysis and those that could correlate with an increased risk of carriage of resistant/non-susceptible strains from a clinical point of view. The following parameters were entered for analysis in the multivariate logistic regression models: age, gender, location of day care center or kindergarten, number of young siblings in the household with age <8 years, hospitalization, recent use of antibiotic by subject, steroid use, history of otitis media and history of respiratory tract infections. A P value of = 0.05 was considered to be statistically significant.

Results

Study population and demographics

Between February and May 2004, consecutive nasopharyngeal swabs and questionnaires were collected from 2595 healthy children (median age ± S.D. 4.3 ± 1.1 years, male: female ratio 1:1), of which, after careful evaluation of the accompanying questionnaires, 2536 were included in the study analysis (2536/2595, i.e. 97.7% of original population). In Table 1, distribution of nasopharyngeal sampling specimens and isolated strains per geographic region is shown. Carriage rates differed significantly among differed regions. In Figure 1, a map of Greece is provided indicating the geographical location of the sampling sites, with the respective sampling population, carriage rates and penicillin resistance rates.
https://static-content.springer.com/image/art%3A10.1186%2F1471-2334-9-120/MediaObjects/12879_2008_Article_885_Fig1_HTML.jpg
Figure 1

Map of Greece with the geographic location of different regions participating in the 2004 Streptococcus pneumoniae nasopharyngeal study For every region, the number of children sampled, the respective carriage rates and penicillin resistance rates (PGR%) are provided in the boxes.

Table 1

Distribution of nasopharyngeal samples and carriage rates of pneumococcal strains per geographic region.

City/Prefecture

Total Number

of children sampled

Number of pneumococcal

strains isolated

Carriage rate

%

Athens.

Attika

932

273

29.29%

Halkida.

Evia

271

138

50.92%*

Thessaloniki.

Central Macedonia

650

122

18.77%*

Ioannina.

Epirus

59

26

44.07%*

Alexandroupolis.

Thrace

102

34

33.33%

Herakleion.

Crete

96

52

54.17%*

Nafplio-Tripoli-Sparti.

Peloponnese

426

101

23.71%

Greece in total

2536

746

29.42%

* flags statistically significant differences at p level of = 0.05. as compared to Attika prefecture

Nasopharyngeal carriage of S pneumoniae strains

A total of 793 pneumococcal strains was isolated in the study from the original 2595 nasopharyngeal specimens (mean carriage rate within study period 793/2595 = 30.55%). Of those, 780 isolates survived shipment and storage and were microbiologically processed, and finally 746 strains were included in the present protocol analysis of the 2536 properly filled questionnaires (mean carriage in per protocol analysis 746/2536 = 29.41%). Carriage of pneumococcal strains was related to age, period and region of sampling, use of antibiotics in the last trimester (last month not included) and history of respiratory infections in the last year. Antibiotic use during the last month did not affect carriage rates of pneumococci. In Table 2, analysis of potential risk factors for nasopharyngeal carriage of pneumococci, as defined by the protocol questionnaire, is listed.
Table 2

Risk factors for carriage of pneumococcal strain.

 

Odds Ratio (OR)

P

95% CI

Gender (boys)

1.019

0.827

0.855–1.211

Age (<3 years old)

0.886

0.001

0.824–0.953

Private vs. public daycare centre

0.862

0.128

0.712–1.043

Antibiotic consumption

   

In the last month

0.866

0.139

0.717–1.040

In the last trimester

1.262

0.009

1.060–1.501

Siblings <8 ys in the family (yes or no)

1.036

0.535

0.926–1.159

History of respiratory tract infections

0.745

0.024

0.577–0.962

History of acute otitis media episodes

1.098

0.288

0.923–1.306

Steroid use

1.074

0.525

0.861–1.340

History of hospital admission

0.751

0.296

0.439–1.285

Parents health-care workers

1.176

0.210

0.912–1.517

Susceptibility testing

In Table 3, results for resistance rates and MIC distribution parameters for all antibiotics tested are shown per region of sampling. Resistance rates differed significantly among different geographic regions. Multiresistant strains formed 23.86% of the carriage isolates (178/746), while combined resistance to penicillin and erythromycin was documented for 75/746 of the total sample (10.05%). No resistance to moxifloxacin and levofloxacin was documented.
Table 3

Distribution of MIC50/MIC90 values and resistance/nonsusceptibility rates per geographic region

City/Prefecture

#

strains

 

PG

CXM

CTX

ERY

COT

TET

CIP

Athens.

 

%ns-%r

37.9–15.8

29.8–28.7

1.8–0.4

33.2–32.1

43.6–26

24.2–23.4

3.8

Attika

273

MIC50/MIC90

0.023–2

0.047–4

0.023–0.75

0.125–256

0.5–32

0.125–24

0.75–1.5

Halkida.

 

%ns-%r

37–15.2

23.9–21.7

1.4–0

39.1–37.7

51.8–29.2

34.8–30.4

3.8

Evia

138

MIC50/MIC90

0.023–2

0.032–3

0.023–0.75

0.125–256

0.75–32

0.19–32

0.75–2

Thessaloniki.

 

%ns-%r

32.8–7.4*

21.3–18

0.8–0

34.2–34.2

38–29.8

21.3–20.5

3.3

Central Macedonia

122

MIC50/MIC90

0.032–1

0.032–2

0.016–0.5

0.125–24

0.5–32

0.25–48

0.75–1.5

Ioannina.

 

%ns-%r

19.2*-7.7*

11.5–11.5

2.9–0

42.3–38.5

42.3–19.2

19.2–19.2

0

Epirus

26

MIC50/MIC90

0.032–1

0.047–3

0.023–0.38

0.25–96

0.5–18

0.125–24

0.5–1

Alexandroupolis.

 

%ns-%r

11.8*-8.8*

8.8–8.8

0–0

17.6*-17.6

35.3–2.9

14.7–11.8

11.8

Thrace

34

MIC50/MIC90

0.023–1

0.023–2

0.023–0.5

0.125–2.5

0.38–2

0.125–24

1–3

Herakleion.

 

%ns-%r

53.8*-25.5*

40.4–34.6

0–0

66.7*-66.7

65.4–26.9

48.1–46.2

6.1

Crete

52

MIC50/MIC90

0.12–2

0.5–6

0.12–0.75

32–256

1–32

1.5–96

0.75–1.5

Nafplio-Tripoli-Sparti.

 

%ns-%r

28.0*-14.0*

24.0–24.0

1.0–0.0

14.0*-14.0

30.0–20.0

21.0–21.0

2.0

Peloponnese

101

MIC50/MIC90

0.023–2

0.023–2

0.023–0.75

0.094–128

1–2

0.125–24

0.75–2

Greece in total

746

%ns-%r

34.8–14.1

25.7–23.9

1.3–0.1

33.8–33

43.8–25.2

26.3–24.8

4.0

  

MIC50/MIC90

0.023–1.5

0.032–3

0.023–0.75

0.125–256

0.5–32

0.125–24

0.75–2

No resistance was recorded for levo- and moxi-floxacin. Respective MIC50/90 values were 0.75–1 and 0.125–0.19 mg/L

PG: penicillin. CXM: cefuroxime. CTX: ceftriaxone. ERY: erythromycin. COT: cotrimoxazole. TET: tetracycline. CIP: ciprofloxacin

*flags statistically significant differences at p level of = 0.05 when compared to Attika region

Risk factors for carriage of resistant pneumococci

Recent antibiotic use in the last month-irrespective of antibiotic class, duration of administration and number of courses of antibiotics- was strongly associated with the isolation of resistant pneumococci to a single or multiple antibiotics. Moreover, increasing number of antibiotic courses in the last month increased the likelihood of isolating a resistant pneumococcal strain Odds Ratio (OR) per antibiotic course for penicillin resistance = 1.35, 95% Confidence Interval (CI) <0.99–1.83> P = 0.05, and OR for erythromycin resistance = 1.43, CI <1.11–1.83> P = 0.004). Combined resistance to penicillin and erythromycin and multiresistance (3 or more classes of antibiotics) were also strongly related to antibiotic use in the month preceding sampling (OR for combined resistance = 2.09, CI <1.24–3.52> P = 0.002, and OR for multiresistance = 2.02, CI <1.38–2.96> P < 0.001). In terms of non-susceptibility (i.e. intermediate and fully resistant strains together), antibiotic use both in the last month and in the preceding 3 months (last month excluded) held a statistically significant correlation with carriage of a penicillin and/or erythromycin non susceptible strain. For children that had received an antibiotic course in the last trimester, the possibility of carrying a resistant (or a non-susceptible) strain in their nasopharynx was even greater, if they had additionally received an antibiotic course in the last month (P < 0.001, OR 4.18 for resistance, 95%CI 2.06–8.54). In Table 4, risk factors for carriage of a resistant or non-susceptible strain are listed in full detail. Carriage of ciprofloxacin resistant strains was independent of antibiotic use.
Table 4

Risk factors for carriage of a resistant or a non-susceptible pneumococcal strain to penicillin and to erythromycin

 

Univariate analysis

Multivariate analysis

 

OR

95%CI

P

OR

95%CI

P

Penicillin resistance

      

Male gender

0.75

0.49–1.15

0.196

0.76

0.48–1.19

0.244

Age <3 years old

0.79

0.66–0.94

0.009

0.76

0.70–1.06

0.164

Sampling period*

0.48

0.31–0.73

0.001

0.57

0.36–0.92

0.023

Antibiotic use in the last month

1.94

1.26–2.98

0.002

2.00

1.26–3.17

0.003

Antibiotic use in the last trimester

1.07

0.70–1.63

0.749

1.09

0.69–1.71

0.696

History of acute otitis media episodes

1.07

0.70–1.63

0.749

0.90

0.54–1.51

0.709

History of respiratory tract infections

0.89

0.50–1.58

0.652

0.96

0.48–1.92

0.928

Other sibling(s) in the household <8 years old

0.96

0.62–1.47

0.814

1.07

0.67–1.71

0.751

Steroid use

1.02

0.64–1.59

0.971

1.20

0.715–2.02

0.486

Admission to the hospital in the last year

2.40

0.83–6.87

0.159

2.57

0.72–9.18

0.145

Prefecture of Thessaloniki**

0.42

0.19–0.9

0.026

0.33

0.13–0.83

0.019

Prefecture of Evia(Halkida)**

1.11

0.66–0.87

0.685

0.91

0.43–1.94

0.825

Prefecture of Evros(Alexandroupolis)**

0.57

0.17–1.92

0.458

0.52

0.14–1.91

0.328

Prefecture of Epirus(Ioannina)**

0.49

0.11–2.13

0.564

0.20

0.01–1.30

0.635

Prefecture of Peloponnese**

0.98

0.53–1.81

1.000

1.09

0.52–2.29

0.803

Prefecture of Herakleion, Crete**

2.17

1.11–4.22

0.036

1.69

0.70–4.07

0.238

Erythromycin resistance

      

Male gender

1.06

0.78–1.45

0.693

1.00

0.72–1.39

0.958

Age <3 years old

0.82

0.72–0.94

0.005

0.866

0.74–1.00

0.061

Sampling period*

0.46

0.33–0.63

< 0.001

0.52

0.37–0.73

< 0.001

Antibiotic use in the last month

1.43

1.04–1.96

0.025

1.92

1.35–2.72

< 0.001

Antibiotic use in the last trimester

1.19

0.87–1.63

0.266

1.30

0.94–1.80

0.112

History of acute otitis media episodes

1.39

1.02–1.90

0.034

1.13

0.78–1.64

0.508

History of respiratory tract infections

0.78

0.50–1.20

0.262

0.57

0.34–0.95

0.031

Other sibling(s) in the household <8 years old

0.93

0.68–1.28

0.686

0.89

0.63–1.26

0.534

Steroid use

1.33

0.96–1.84

0.081

1.20

0.81–1.77

0.356

Admission to the hospital in the last year

0.77

0.27–2.19

0.801

0.87

0.23–3.23

0.846

Prefecture of Thessaloniki**

1.06

0.70–1.61

0.752

0.99

0.56–1.75

0.993

Prefecture of Evia(Halkida)**

1.29

0.87–1.89

0.194

1.03

0.59–1.78

0.913

Prefecture of Evros(Alexandroupolis)**

0.42

0.17–1.03

0.061

0.50

0.19–1.32

0.165

Prefecture of Epirus(Ioannina)**

1.28

0.57–2.86

0.531

1.39

0.51–3.80

0.516

Prefecture of Peloponnese**

0.36

0.36–0.97

0.017

0.41

0.21–0.81

0.010

Prefecture of Herakleion, Crete**

4.22

2.24–7.98

< 0.001

3.26

1.55–6.84

0.002

Penicillin nonsusceptibility

      

Male gender

0.89

0.79–1.47

0.638

0.89

0.65–1.23

0.499

Age <3 years old

0.78

0.68–0.89

< 0.001

0.82

0.71–0.96

0.013

Sampling period*

0.5

0.37–0.69

< 0.001

0.58

0.42–0.82

0.002

Antibiotic use in the last month

1.71

1.23–2.38

0.001

1.66

1.17–2.35

0.004

Antibiotic use in the last trimester

1.36

1.00–1.84

0.045

1.48

1.07–2.04

0.017

History of acute otitis media episodes

1.04

0.77–1.41

0.815

0.82

0.56–1.18

0.297

History of respiratory tract infections

1.06

0.68–1.65

0.825

1.13

0.68–1.89

0.624

Other sibling(s) in the household <8 years old

0.84

0.61–1.28

0.686

0.85

0.61–1.20

0.379

Steroid use

1.30

0.95–1.79

0.102

1.36

0.93–2.01

0.108

Admission to the hospital in the last year

1.52

0.59–3.91

0.453

1.97

0.61–6.32

0.251

Prefecture of Thessaloniki**

0.89

0.59–1.35

0.678

0.48

0.27–0.86

0.014

Prefecture of Evia(Halkida)**

1.12

0.76–1.64

0.554

0.73

0.42–1.26

0.265

Prefecture of Evros(Alexandroupolis)**

0.21

0.074–0.63

0.005

0.19

0.06–0.57

0.003

Prefecture of Epirus(Ioannina)**

0.43

0.16–1.16

0.098

0.17

0.03–0.81

0.026

Prefecture of Peloponnese**

0.69

0.43–1.10

0.143

0.70

0.40–1.22

0.215

Prefecture of Herakleion, Crete**

1.91

1.05–3.48

0.003

1.39

0.68–2.62

0.357

Erythromycin nonsusceptibility

      

Male gender

1.08

0.79–1.47

0.638

1.02

0.74–1.41

0.881

Age <3 years old

0.8

0.7–0.92

0.002

0.84

0.72–0.97

0.023

Sampling period*

0.46

0.34–0.64

< 0.001

0.53

0.37–0.74

< 0.001

Antibiotic use in the last month

1.81

1.3–2.52

< 0.001

1.86

1.31–2.64

< 0.001

Antibiotic use in the last trimester

1.44

1.05–1.97

0.021

1.32

0.95–1.82

0.091

History of acute otitis media episodes

1.44

1.06–1.96

0.019

1.16

0.80–1.67

0.426

History of respiratory tract infections

0.77

0.50–1.19

0.263

0.65

0.34–0.94

0.028

Other sibling(s) in the household <8 years old

0.97

0.71–1.33

0.873

0.92

0.65–1.30

0.662

Steroid use

1.26

0.91–1.73

0.610

1.13

0.77–1.67

0.519

Admission to the hospital in the last year

0.74

0.26–2.11

0.802

0.86

0.23–3.17

0.820

Prefecture of Thessaloniki**

1.02

0.67–1.54

0.916

0.92

0.52–1.62

0.794

Prefecture of Evia(Halkida)**

1.33

0.90–1.95

0.162

1.12

0.65–1.94

0.671

Prefecture of Evros(Alexandroupolis)**

0.40

0.16–0.99

0.042

0.46

0.17–1.21

0.120

Prefecture of Epirus(Ioannina)**

1.45

0.65–3.22

0.399

1.59

0.60–4.25

0.347

Prefecture of Peloponnese**

0.34

0.12–0.92

0.002

0.38

0.2–0.75

0.005

Prefecture of Herakleion, Crete**

4.02

2.13–7.58

< 0.001

3.39

1.61–7.17

0.005

* reference category for period of sampling: February

** reference category for prefecture of sampling: Athens, prefecture of Attika

Use of antibiotics and resistance

A significant number of children from the total study population had at least one antibiotic course in the month preceding sampling (31.03%) or in the previous trimester (42.43%). Administration of antibiotics did not differ among geographic regions. The majority of antibiotic courses in the carriers' group were prescribed by a doctor either in the preceding month (92.5%) or trimester (87.8%). The rest of the consumed antibiotics were purchased over the counter by parents' initiative (5.55% and 9.8%) or by pharmacists' advice (1.85% and 2.3% of cases for the last month and trimester respectively).

The most common infections for prescribing an antibiotic were similar in rates in both groups (carriers and non-carriers). Rates for most common causes were as follows: acute otitis media 33.56 – 31%, tonsillitis 13.34 – 11%, lower respiratory tract infections 4.26 – 4%, and virus-related respiratory tract infections 28.2 – 28% (mostly rhinopharyngitis, tracheobronchitis and laryngitis), respectively for each group. Most commonly prescribed antibiotics were amoxicillin-clavulanate (35%) and oral 2nd generation cephalosporins (31%), namely cefaclor, cefprozil and cefuroxime axetil.

Serotype distribution

Among the 380 pneumococcal strains displaying resistance to at least 1 antibiotic class, serotyping was available for 317 strains (83.5% of resistant strains). The distribution of serotypes per geographic region and the respective coverage of the heptavalent pneumococcal conjugate vaccine is presented in Table 5. Serotypes 19F, 14, 9V, 23F and 6B formed 70.6% of the total number of resistant strains serotyped.
Table 5

Serotype distribution among pneumococcal strains displaying resistance to at least one antibiotic class (n = number of strains, % = percent of strains per geographic region).

 

Athens

(n, %)

Halkida

(n, %)

Thessaloniki

(n, %)

Ioannina

(n, %)

Alexandroupolis

(n, %)

Herakleion

(n, %)

Peloponnese

(n, %)

Total

(n,%)

PCV7* serotypes

80 (70.17)

42 (73.68)

33 (58.92)

10 (76.92)

6 (54.55)

25 (75.76)

30 (90.91)

226 (71.29)

19F

32 (28.07)

20 (35.09)

9 (16,07)

2 (15.38)

3 (27.27)

11 (33.33)

10 (30.3)

87 (27.44)

14

10 (8.77)

6 (10.53)

10 (17.86)

  

11 (33.33)

3 (9.09)

40 (12.62)

9V

20 (17.54)

 

2 (3.57)

2 (15.38)

  

10 (30.3)

34 (10.73)

23F

10 (8.77)

6 (10.53)

6 (10.71)

5 (38.46)

1 (9.09)

1 (3.04)

4 (12.13)

33 (10.41)

6B

8 (7.02)

10 (17.54)

5 (8.93)

1 (7.69)

2 (18.18)

2 (6.06)

2 (6.06)

30 (9.46)

18C

  

1 (1.79)

   

1 (3.03)

2 (0.63)

PCV7-related serotypes

17 (14.92)

10 (17.55)

11 (19.66)

0

2 (18.18)

4 (12.12)

0

43 (13.56)

6A

7 (6.14)

3 (5.26)

5 (8.93)

 

0

2 (6.06)

 

17 (5.36)

Other related

10 (8.78)

7 (12.29)

6 (10.73)

 

2 (18.18)

2 (6.06)

 

26 (8,20))

Non PCV7 serogroups

10 (8.77)

3 (5.26)

8 (14.28)

3 (23.08)

1 (9.09)

2 (6.06)

3 (9.09)

32 (10.1)

Nontypeable strains

7 (6.14)

2 (3.51)

4 (7.14)

0

2 (18.18)

2 (6.06)

0

16 (5.05)

Total

114 (100)

57 (100)

56 (100)

13 (100)

11 (100)

33 (100)

33 (100)

317 (100)

*PCV7: heptavalent pneumococcal conjugate vaccine

Discussion

The present study is the first surveillance study conducted in Greece at nation-wide level in the pre-vaccination era, with representative samples per geographical region, according to the age-specific population distribution in the most recent records of the National Registry in March 2001 [12].

Carriage rates in the present study varied significantly with age, period of sampling and the geographic area visited. This significant trend differentiation stresses the importance of sequential sampling in a specific area and multifocal sampling at a specific time-point, as useful tools in the epidemiological studies of resistance. It must be noted that regional differences in carriage rates did not affect resistance/nonsusceptibility rates. Resistance rates differed among different regions. This difference per region renders the results of a multicenter study even more valuable, as it may predict similar trends in the clinical isolates [13]. In the present study serotyping was performed only in the resistant strain population. Thus, the association of specific serotypes with specific resistance patterns cannot be accurately performed and regional variability in resistance rates for penicillin and erythromycin in relation to serotype distribution requires caution.

One of the risk factors amenable to intervention for carrying a resistant or a non-susceptible pneumococcal strain in the nasopharynx for a healthy preschool child was the use of antibiotics in the month preceding sampling. Additionally, antibiotic use was related to the isolation of combined penicillin-erythromycin resistant, as well as multiresistant pneumococcal strains Numerous studies [1416] have pointed out antibiotic consumption as a very strong pressure factor for the development of resistance, irrespective of ecological setting (individuals-community). Chung et al [17] have recently shown that prescription of amoxicillin doubled the risk of recovery of β lactamase producing Haemophilus influenzae strains. Although this effect was transitory at an individual level (2 weeks), it was sufficient to sustain a high level of antibiotic resistance in the study population.

Acute otitis media was the most frequent infection for which a child received antibiotics in our study. Nonetheless, a similar proportion of children (approx. 30%) consumed antibiotics for infections which seemed to be of viral cause by all descriptions in the questionnaire used. It must be stressed that acute otitis media does not always require prompt administration of antibiotics, as it may be of viral origin in certain cases. In Finland Palmu et al recorded negative cultures of middle ear fluid in approximately 35% of children with acute otitis media in 2004 [18]. Moreover, a wait-and-see approach to acute otitis media treatment in the paediatric population seems to reduce antibiotic consumption and subsequent resistance without jeopardizing children's safety and well-being [19].

Approximately 90% of the prescriptions originated from practicing physicians in the community, while in the remaining 10% of cases, parents had access to antibiotics without doctor's prescription, although this is not abiding by antibiotics policy law [20]. As demonstrated by Guillemot et al [21], intensive educational strategies, targeting to optimize antibiotic use both in terms of indications and of dose/duration of administration, significantly reduced the colonization with penicillin non-susceptible pneumococci in areas with high prevalence of resistance.

The heptavalent pneumococcal vaccination (PCV7) covered 71.32% of resistant strains in total in the present study. The most prevalent serotypes in our population carried the heavier burden of antibiotic resistance. Implementation of the heptavalent vaccine has been shown to be highly efficacious in decreasing the incidence of vaccine-type antibiotic-resistant strains in disease and colonization [5]. A study by Grivea et al[8], at a regional level in Thessaly, Central Greece between 2005–2007, showed that increasing rates of PCV7 population coverage was associated with a reduction in colonization by PCV7-related serotypes in vaccinated (from 33% to 8.6%, P < 0.001) and unvaccinated children (from 36% to 17%, P = 0.05). Moreover, a decrease in the rate of highly penicillin resistant pneumococcal isolates was recorded only in vaccinated children (from 11% to 0.6%, P = 0.001), whereas rates for penicillin intermediate strains were not affected.

In a community setting of high antibiotic consumption, Frazao et al[22] showed that PCV7 vaccination was successful in the reduction of vaccine related strains, but it did not change the frequency of nasopharyngeal carriage of drug resistant pneumococci, implying the crucial role of antibiotic consumption on the serotype replacement phenomenon by drug-resistant non-vaccine related pneumococcal strains.

To reduce antibiotic resistance in the community, reducing unnecessary antibiotic prescriptions combined with the implementation of the heptavalent conjugate pneumococcal vaccine are probably two of the most efficient strategies. In a large scale prospective study in France from 2001 to 2005 in children presenting with acute otitis media, Cohen et al [23] showed that unvaccinated children who had received antibiotics within the last three months had a 4-fold greater risk of carrying a penicillin resistant strain than vaccinated children who had not received antibiotics. Moreover, vaccination reduced the antibiotic consumption from 51.6% to 38.5%, as well as the risk for a child to carry a penicillin resistant pneumococcal strain from 15% to 3%.

Conclusion

Colonization with a pneumococcal strain is a usual event in the everyday life of preschool children. Epidemiological data derived from the present surveillance study stress the importance of recent antibiotic use in the colonization of otherwise healthy children's nasopharynx by resistant strains of S pneumoniae. The heptavalent pneumococcal conjugate vaccine, as shown from the serotype distribution in the pre-vaccination era, could provide coverage against the majority of resistant strains. In settings with a high antibiotic consumption profile in the community, like the one described in the present study, prudent use of antibiotics at an individual level coupled with vaccination could prove helpful in decreasing pneumococcal resistance rates in the community, thus facilitating treatment of pneumococcal infection.

Declarations

Acknowledgements

We thank all the participating children and their parents and teachers, as well as the participating investigators of the study group.

Hellenic Study Group for the Susceptibility of Streptococcus pneumoniae 2004. ATTIKON University General Hospital (co-ordinating center): H. Giamarellou, K Kanellakopoulou, I. Galani, D. Hatzaki, D. Katsala, I. Katsarolis, I. Matthaiopoulou, K. Orlandou, G. Poulakou, R. Vorou, L. Zerva; 'P&A Kyriakou' Children's Hospital of Athens: M. Foustoukou, D.A. Kafetzis, I. Paraskakis, C. Skevaki; 'Aghia Sophia' Children's Hospital of Athens: A. Pangalis, V. Syriopoulou; 'Laikon' General Hospital of Athens: G.L. Daikos, A. Avlamis;'Sotiria' General Hospital of Athens: S. Kanavaki, S. Karabela, E. Kastrisiou, M. Makarona; 'Hippokration' General Hospital of Thessaloniki: C. Antachopoulos, E. Roilides, D. Sofianou; Hospital for Infectious Diseases of Thessaloniki: L. Ftika, A. Kansouzidou, I. Kavaliotis, M. Kazantzi;'G. Papanikolaou' Hospital of Thessaloniki: I. Kioumis, H. Tsorlini; University Hospital of Ioannina: C. Koubaniou, K. Konstantopoulos, S. Leveidiotou, V. Papatolis; University Hospital of Larissa: I. Gourgoulianis, I. Papageorgiou, V. Tsolaki; University Hospital of Alexandroupolis: I. Pneumatikos; University Hospital of Heraklion: M. Rovithi, G. Samonis.

Authors’ Affiliations

(1)
4th Dept of Internal Medicine, Athens Medical School, ATTIKON University General Hospital
(2)
Department of Hygiene and Epidemiology, Athens Medical School
(3)
3rd Dept of Pediatrics, Aristotle University of Thessaloniki, Hippokration Hospital
(4)
2nd Dept of Pediatrics, Athens Medical School, P. & A. Kyriakou Children's Hospital
(5)
1st Dept of Propaedeutic Medicine, Athens Medical School, Laiko General Hospital
(6)
Pneumonology Department, University of Ioannina Medical School
(7)
Alexandroupolis University Hospital, Democritus University of Thrace Medical School
(8)
Department of Internal Medicine, University Hospital of Herakleion
(9)
1st Department of Pediatrics, Athens Medical School, Aghia Sophia Children's Hospital

References

  1. Bogaert D, De Groot R, Hermans PW: Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004, 4: 144-154. 10.1016/S1473-3099(04)00938-7.View ArticlePubMedGoogle Scholar
  2. Mera RM, Miller LA, Daniels JJ, Weil JG, White AR: Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis. 2005, 51: 195-200. 10.1016/j.diagmicrobio.2004.10.009.View ArticlePubMedGoogle Scholar
  3. Baquero F, Baquero-Artigao G, Canton R, Garcia-Rey C: Antibiotic consumption and resistance selection in Streptococcus pneumoniae. J Antimicrob Chemother. 2002, 50 (Suppl S2): 27-37. 10.1093/jac/dkf504.View ArticlePubMedGoogle Scholar
  4. De Lencastre H, Tomasz A: From ecological reservoir to disease: the nasopharynx, day-care centers and drug-resistant clones of Streptococcus pneumoniae. J Antimicrob Chemother. 2002, 50 (Suppl S2): 75-81. 10.1093/jac/dkf511.View ArticlePubMedGoogle Scholar
  5. Leibovitz E: The effect of vaccination on Streptococcus pneumoniae resistance. Curr Infect Dis Rep. 2008, 10: 182-191. 10.1007/s11908-008-0031-x.View ArticlePubMedGoogle Scholar
  6. Syrogiannopoulos GA, Grivea IN, Katopodis GD, Geslin P, Jacobs MR, Beratis NG: Carriage of antibiotic-resistant Streptococcus pneumoniae in Greek infants and toddlers. Eur J Clin Microbiol Infect Dis. 2000, 19: 288-93. 10.1007/s100960050477.View ArticlePubMedGoogle Scholar
  7. Volonakis K, Souli M, Kapaskelis A, Baziaka F, Grammelis V, Ziakas PD, Giamarellou H: Evolution of resistance patterns and identification of risk factors for Streptococcus pneumoniae colonisation in daycare centre attendees in Athens, Greece. Int J Antimicrob Agents. 2006, 28: 297-301. 10.1016/j.ijantimicag.2006.07.002.View ArticlePubMedGoogle Scholar
  8. Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA: Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr Infect Dis J. 2008, 27: 519-525. 10.1097/INF.0b013e318168d28a.View ArticlePubMedGoogle Scholar
  9. Poulakou G, Katsarolis I, Matthaiopoulou I, Tsiodras S, Kanavaki S, Hatzaki D, Roilides E, Sofianou D, Kavaliotis I, Kansouzidou A, Kafetzis DA, Paraskakis I, Foustoukou M, Daikos GL, Syriopoulou V, Pangalis A, Leveidiotou S, Giamarellou H: Nationwide surveillance of Streptococcus pneumoniae in Greece: patterns of resistance and serotype epidemiology. Int J Antimicrob Agents. 2007, 30: 87-92. 10.1016/j.ijantimicag.2007.03.011.View ArticlePubMedGoogle Scholar
  10. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing. M100-S14. Wayne, PA, USA. 2004, 10.1097/00006454-199804000-00004.Google Scholar
  11. Fluoroquinolones. EUCAST clinical MIC breakpoints. 2006. [http://www.srga.org/eucastwt/MICTAB/MICquinolones.htm]
  12. General Secretariat of National Statistical Service of Greece. [http://www.statistics.gr/StatMenu.asp]
  13. Kellner JD, McGeer A, Cetron MS, Low DE, Butler JC, Matlow A, Talbot J, Ford-Jones EL: The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatr Infect Dis J. 1998, 17: 279-286. 10.1097/00006454-199804000-00004.View ArticlePubMedGoogle Scholar
  14. Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S: Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ. 1996, 313: 387-391. 10.1089/mdr.2006.12.169.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Arason VA, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson KG: The role of antimicrobial use in the epidemiology of resistant pneumococci: A 10-year follow up. Microb Drug Resist. 2006, 12: 169-176. 10.1007/s100960050202.View ArticlePubMedGoogle Scholar
  16. Melander E, Molstad S, Persson K, Hansson HB, Soderstrom M, Ekdahl K: Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children. Eur J Clin Microbiol Infect Dis. 1998, 17: 834-838. 10.1136/bmj.39274.647465.BE.View ArticlePubMedGoogle Scholar
  17. Chung A, Perera R, Brueggemann AB, Elamin AE, Harnden A, Mayon-White R, Smith S, Crook DW, Mant D: Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ. 2007, 335: 429-10.1086/380642.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Palmu AA, Herva E, Savolainen H, Karma P, Makela PH, Kilpi TM: Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis. 2004, 38: 234-242. 10.1097/MOP.0b013e3282f2fa62.View ArticlePubMedGoogle Scholar
  19. Spiro DM, Arnold DH: The concept and practice of a wait-and-see approach to acute otitis media. Curr Opin Pediatr. 2008, 20: 72-78. 10.1093/jac/dkl457.View ArticlePubMedGoogle Scholar
  20. Grigoryan L, Burgerhof JG, Haaijer-Ruskamp FM, Degener JE, Deschepper R, Monnet DL, Di Matteo A, Scicluna EA, Bara AC, Lundborg CS, Birkin J: Is self-medication with antibiotics in Europe driven by prescribed use?. J Antimicrob Chemother. 2007, 59: 152-156. 10.1086/432721.View ArticlePubMedGoogle Scholar
  21. Guillemot D, Varon E, Bernede C, Weber P, Henriet L, Simon S, Laurent C, Lecoeur H, Carbon C: Reduction of antibiotic use in the community reduces the rate of colonization with penicillin G-nonsusceptible Streptococcus pneumoniae. Clin Infect Dis. 2005, 41: 930-938. 10.1097/01.inf.0000154326.77617.3e.View ArticlePubMedGoogle Scholar
  22. Frazão N, Brito-Avô A, Simas C, Saldanha J, Mato R, Nunes S, Sousa NG, Carriço JA, Almeida JS, Santos-Sanches I, de Lencastre H: Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon. Pediatr Infect Dis J. 2005, 24: 243-252. 10.1097/01.inf.0000243163.85163.a8.View ArticlePubMedGoogle Scholar
  23. Cohen R, Levy C, de La Roque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E: Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006, 25: 1001-1007. 10.1097/01.inf.0000243163.85163.a8.View ArticlePubMedGoogle Scholar
  24. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/9/120/prepub

Copyright

© Katsarolis et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement